ClinicalTrials.gg
RecruitingNCT06450730Updated Oct 13, 2026

Effectiveness of a Combined mHealth-CBT Psychological Intervention to Improve Psychological Well-Being in Young Patients With T1D

An interventional study of Cognitive-Behavioral Therapy: face-to-face + app in Diabetes Mellitus, Type 1, sponsored by Maimónides Biomedical Research Institute of Córdoba. Recruiting at 1 site in Spain. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Maimónides Biomedical Research Institute of Córdoba · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Feb 2023, registered Jun 2024).
  • Started Feb 2023; still recruiting 3 years 9 months later.
Updated Oct 13, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
122
Allocation
Non-randomized
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain — 25 open to participants now, 30 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · Spain.

Planned enrollment
61st of 113
122 · median 153
Started
2023
with 7 others
No phase
55 of 150
12 open now
Primary completion
2026-12
later than 12 of 29 live
Registered
116th of 150
by date

Among the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, this one is the 61st largest by planned enrollment of the 113 interventional ones that give a count, is one of 8 that started in 2023, is one of 55 with no phase, reaches primary completion later than 12 of the 29 other live ones, and was the 116th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

25 of the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, or all of them as a file.
02

Study summary

Type 1 diabetes (T1D) can lead to psychological adjustments that impact the acceptance and management of this health condition, as well as the overall quality of life of patients, especially among the young. Therefore, there is a need for psychological interventions aimed at enhancing the psychological well-being of children and adolescents with T1D. The goal of this non-randomized controlled trial is to evaluate whether a combined intervention comprising mHealth (using an app) and face-to-face psychological sessions based on Barlow's protocol and cognitive-behavioral therapy techniques (CBT) is effective in enhancing psychological well-being in children and adolescents with T1D. The main hypotheses are:

  • H1: The primary results expected to be obtained are a significant increase in psychological well-being, which means a decreased diabetes distress (DDS) (H1a) an increased subjective well-being (PANAS) (H1b) and a better self-efficacy for managing their emotions (RESE) (H1c).
  • H2: As secondary outcomes, it is also expected that the combined mHealth-CBT intervention would increase the level of positivity (P-Scale) (H2a), the self-esteem (RSES) (H2b) and the satisfaction with life (SWLS) (H2c).
03

Conditions studied

  • Diabetes Mellitus, Type 1

Keywords

  • Type 1 Diabetes
  • Cognitive-behavioral Therapy
  • mHealth interventions
  • Psychological well-being
04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Girls and Boys with a diagnosis of T1D 6 - 18
  • Having a smartphone compatible with the APP created used for the mHealth intervention and daily access to internet
  • Having the required digital skills to follow the mHealth intervention
  • Not currently participating in another clinical trial involving a psychological intervention

Exclusion criteria

Exclusion Criteria:

  • Girls and Boys with a diagnosis of T1D >18 years
  • Not Having a smartphone compatible with the APP created used for the mHealth intervention and daily access to internet
  • Currently participating in another clinical trial involving a psychological intervention
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
122 participants (estimated)

Study arms

  • Experimental
    CBT face-to-face + app

    Combines face-to-face CBT sessions with online activities and resources trough a mobile app

    Behavioral: Cognitive-Behavioral Therapy: face-to-face + app

  • No intervention
    TAU Group

    TAU Group Patients of the control group continued their usual treatment.

Interventions

  • BehavioralCognitive-Behavioral Therapy: face-to-face + app

    This group will receive three 1-hour face-to-face CBT sessions (1,3,8). Participants will be involved in psychoeducation and practical activities related to psychological variables crucial for the adequate management of the disease (emotion regulation, self-efficacy, psychological flexibility, decision-making, etc.). These activities will include role-playing, discussions, and assignments to highlight the importance of emotions, thoughts, and healthy behaviors in managing diabetes and and their impact on the quality of life. For the online sessions, an app will be developed to complement the face-to-face intervention. Participants will engage in 5-weeks of exercises with weekly activities related to the intervention content (2,5,6,7). The structure of the activities will mirror that of the face-to-face sessions and will include tasks, self-report instruments, reinforcement and activity monitoring. In addition, the app will incoportate multiple resources (texts, slides, videos).

06

What researchers measure

Primary outcomes

  1. Diabetes Distress

    Diabetes Distress Scale (DDS; Polonsky et al., 2005) is a Likert-type scale of 17 items that measures the level of emotional distress related to diabetes in individuals living with this chronic condition and how it impacts their quality of life. Scores ranges from 1 "not a problem" to 5 "very serious problem".

    Time frame: Baseline, immediately after intervention and four months later (follow-up)

  2. Regulatory Emotional Self-Efficacy

    Regulatory Emotional Self-Efficacy scale (RESE; Caprara \& Gervino, 2001).It is designed to assess an individual's perceived self-efficacy in managing negative and expressing positive emotions. It is a five-point scale (1 = not capable at all; 5 = completely capable) to 12 items distributed across two factors: positive affect expression (4 items) and negative affect expression, further divided into handling dejection and distress (4 items), and handling anger and irritation (4 items).

    Time frame: Baseline, immediately after intervention and four months later (follow-up)

  3. Positive Affect and Negative Affect

    Positive Affect and Negative Affect Scale (PANAS; Watson et al., 1988) It is a Likert-type scale of 20-item (10 items for positive and 10 items for negative affect, that assesses the extent to which the participants experienced positive affect in the last 2 weeks. Rated on a 5-point scale from 1 "not at all" to 5 "very much". It has been validated in Spanish (López-Gomez, et al., 2015)

    Time frame: Baseline, immediately after intervention and four months later (follow-up)

Secondary outcomes

  1. Positivity

    The Positivity Scale (P Scale; Zuffianò et al., 2019) evaluates the predisposition of people to estimate their life and their experiences from a positive perspective. It is an 8-item Likert-type scale, ranging from 1 "completely false" to 5 "completely true".

    Time frame: Baseline, immediately after intervention and four months later (follow-up)

  2. Self-esteem

    Rosenberg self-esteem scale (RSES; Rosenberg, 1965). The RSES is a10-item scale that measures global self-worth by measuring both positive and negative feelings about the self. The scale is believed to be uni-dimensional. All items are answered using a 4-point Likert scale format ranging from 1 "strongly disagree" to 5 "strongly agree".

    Time frame: Baseline, immediately after intervention and four months later (follow-up)

  3. Satisfaction with Life

    Satisfaction with Life Scale (SWLS, Diener et al., 1985; Spanish adaptation by Atienza et al., 2000). The SWLS employs a 7-point Likert-style response scale with 5 items, ranging from 1 "completely disagree" to 5 "totally agree".

    Time frame: Baseline, immediately after intervention and four months later (follow-up)

07

Study locations

1 of 1 sites recruiting
  • Reina Sofía University Hospital
    Córdoba, Córdoba 14004, Spain
    Recruiting
    • Bárbara Luque, PhD · Contactbluque@uco.es · +34 957218961
    • Bárbara Luque, PhD · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2026, 46 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 46 months is above that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jul 2026 → Dec 2026 and completion Sep 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2024
First posted
Jun 10, 2024
StartActual
Feb 11, 2023
Primary completionEst.
Dec 2026was Jul 2026
CompletionEst.
Apr 2027was Sep 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 13, 2026
Sites
Reina Sofía University Hospital is now Recruiting
Oct 13, 2026
Primary completion
Jul 2026→Dec 2026
Oct 13, 2026
Study completion
Sep 2026→Apr 2027
Oct 13, 2026
Contact
Study contact now listed: added r•••@uco.es · •••8923; added b•••@uco.es. See the current contact
Oct 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Reina Sofía University Hospital · Córdoba, SpainContact added b•••@uco.es · •••8961Contact added (no phone or email listed)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Active, not recruiting→Recruiting
    Reina Sofía University Hospital is now Recruiting
    Primary completion Jul 2026→Dec 2026
    Study completion Sep 2026→Apr 2027
    Contact Study contact now listed: added r•••@uco.es · •••8923; added b•••@uco.es. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Reina Sofía University Hospital · Córdoba, SpainContact added b•••@uco.es · •••8961Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06450730
Lead sponsor
Maimónides Biomedical Research Institute of Córdoba
Collaborators
Universidad de Córdoba
Responsible party
Rosario Castillo-Mayén (Dr, Maimónides Biomedical Research Institute of Córdoba) — Principal investigator
First posted
Jun 10, 2024
Start date
Feb 11, 2023
Primary completion
Dec 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Rosario Castillo-Mayén, PhD
Contact
rcmayen@uco.es
+34 957218923
Bárbara Luque, PhD
Contact
bluque@uco.es
Bárbara Luque, PhD
principal investigator · Universidad de Córdoba
Carmen Tabernero, PhD
principal investigator · University of Salamanca

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion